AGEN
Price
$6.09
Change
-$0.06 (-0.98%)
Updated
Jul 21 closing price
Capitalization
166.97M
GERN
Price
$1.23
Change
-$0.01 (-0.81%)
Updated
Jul 21 closing price
Capitalization
783.41M
16 days until earnings call
Interact to see
Advertisement

AGEN vs GERN

Header iconAGEN vs GERN Comparison
Open Charts AGEN vs GERNBanner chart's image
Agenus
Price$6.09
Change-$0.06 (-0.98%)
Volume$751.08K
Capitalization166.97M
Geron
Price$1.23
Change-$0.01 (-0.81%)
Volume$8.29M
Capitalization783.41M
AGEN vs GERN Comparison Chart in %
Loading...
AGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GERN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AGEN vs. GERN commentary
Jul 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGEN is a Hold and GERN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 22, 2025
Stock price -- (AGEN: $6.09 vs. GERN: $1.23)
Brand notoriety: AGEN and GERN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AGEN: 52% vs. GERN: 81%
Market capitalization -- AGEN: $166.97M vs. GERN: $783.41M
AGEN [@Biotechnology] is valued at $166.97M. GERN’s [@Biotechnology] market capitalization is $783.41M. The market cap for tickers in the [@Biotechnology] industry ranges from $286.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AGEN’s FA Score shows that 0 FA rating(s) are green whileGERN’s FA Score has 0 green FA rating(s).

  • AGEN’s FA Score: 0 green, 5 red.
  • GERN’s FA Score: 0 green, 5 red.
According to our system of comparison, AGEN is a better buy in the long-term than GERN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AGEN’s TA Score shows that 5 TA indicator(s) are bullish while GERN’s TA Score has 3 bullish TA indicator(s).

  • AGEN’s TA Score: 5 bullish, 4 bearish.
  • GERN’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, AGEN is a better buy in the short-term than GERN.

Price Growth

AGEN (@Biotechnology) experienced а -10.83% price change this week, while GERN (@Biotechnology) price change was -8.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.37%. For the same industry, the average monthly price growth was +15.66%, and the average quarterly price growth was +33.77%.

Reported Earning Dates

AGEN is expected to report earnings on May 12, 2025.

GERN is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+2.37% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GERN($783M) has a higher market cap than AGEN($167M). AGEN YTD gains are higher at: 122.263 vs. GERN (-65.254). AGEN has higher annual earnings (EBITDA): -81.06M vs. GERN (-114.49M). GERN has more cash in the bank: 397M vs. AGEN (18.5M). AGEN has less debt than GERN: AGEN (92M) vs GERN (122M). GERN has higher revenues than AGEN: GERN (116M) vs AGEN (99.5M).
AGENGERNAGEN / GERN
Capitalization167M783M21%
EBITDA-81.06M-114.49M71%
Gain YTD122.263-65.254-187%
P/E Ratio0.21N/A-
Revenue99.5M116M86%
Total Cash18.5M397M5%
Total Debt92M122M75%
FUNDAMENTALS RATINGS
AGEN vs GERN: Fundamental Ratings
AGEN
GERN
OUTLOOK RATING
1..100
1355
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
92
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
3592
P/E GROWTH RATING
1..100
9773
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GERN's Valuation (92) in the Biotechnology industry is in the same range as AGEN (97). This means that GERN’s stock grew similarly to AGEN’s over the last 12 months.

GERN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AGEN (100). This means that GERN’s stock grew similarly to AGEN’s over the last 12 months.

GERN's SMR Rating (97) in the Biotechnology industry is in the same range as AGEN (100). This means that GERN’s stock grew similarly to AGEN’s over the last 12 months.

AGEN's Price Growth Rating (35) in the Biotechnology industry is somewhat better than the same rating for GERN (92). This means that AGEN’s stock grew somewhat faster than GERN’s over the last 12 months.

GERN's P/E Growth Rating (73) in the Biotechnology industry is in the same range as AGEN (97). This means that GERN’s stock grew similarly to AGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AGENGERN
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
72%
Momentum
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
85%
MACD
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 6 days ago
84%
Bullish Trend 6 days ago
74%
Declines
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
76%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
84%
Aroon
ODDS (%)
Bullish Trend 5 days ago
69%
Bearish Trend 1 day ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
AGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GERN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CFWCX26.88N/A
N/A
Calvert Global Water C
WMCVX9.55N/A
N/A
Wasatch Small Cap Value
LEGCX53.03N/A
N/A
Columbia Large Cap Growth C
AFPIX4.54N/A
N/A
DSS AmericaFirst Income I
DLACX15.92N/A
N/A
BNY Mellon Large Cap Equity Y

AGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, AGEN has been closely correlated with TAOX. These tickers have moved in lockstep 91% of the time. This A.I.-generated data suggests there is a high statistical probability that if AGEN jumps, then TAOX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AGEN
1D Price
Change %
AGEN100%
-0.98%
TAOX - AGEN
91%
Closely correlated
-8.90%
ALLR - AGEN
87%
Closely correlated
-2.30%
NRXP - AGEN
83%
Closely correlated
+1.36%
PALI - AGEN
81%
Closely correlated
+26.25%
AXON - AGEN
42%
Loosely correlated
-0.60%
More

GERN and

Correlation & Price change

A.I.dvisor indicates that over the last year, GERN has been loosely correlated with SER. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if GERN jumps, then SER could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GERN
1D Price
Change %
GERN100%
-0.81%
SER - GERN
66%
Loosely correlated
-0.19%
LIANY - GERN
53%
Loosely correlated
-1.82%
VCYT - GERN
44%
Loosely correlated
-2.04%
DAWN - GERN
41%
Loosely correlated
N/A
IDYA - GERN
38%
Loosely correlated
+1.02%
More